HAL (France)open access
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo
0, GLP-1 receptor agonist, Cardiovascular outcomes trial, Renal function, Semaglutide, Kidney function
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 280259
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.